AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|
13.5 C
New York
Tuesday, October 20, 2026

Tag: cell

newsFORsourcecompanycontentinformation1releasesmarket

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

re:BOND Hair Launches AMINOFIXX™ Daily Miracle Bond³ Building Spray – Advanced Solution for Hair Damage at the Molecular Level

FORT LAUDERDALE, Fla., Aug. 15, 2025 /PRNewswire/ -- re:BOND Molecular Hair Science is excited to announce the launch of AMINOFIXX™ Daily Miracle Bond³ Building...

Next Hydrogen Reports Q2 2025 Financial Results

MISSISSAUGA, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the second quarter ended June 30, 2025.

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

T1 Energy and Corning Deal Accelerates ‘Made in America’ Solar Momentum

T1 Energy and Corning Deal Boosts U.S. solar supply chain, advances towards domestic solar modules.

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...

Ahead of Its Historic Listing on Nasdaq, Kyivstar Group Completes Business Combination with Cohen Circle

Kyiv, New York, Dubai, and Philadelphia – 14 August 2025  - VEON Ltd. (Nasdaq: VEON) (“VEON”), a global digital operator and parent company of Ukraine’s leading digital operator JSC Kyivstar (“Kyivstar”), and Cohen Circle Acquisition Corp. I (Nasdaq: CCIR) (“Cohen Circle”), a special purpose acquisition company, have today closed the previously announced business combination between Kyivstar Group Ltd. and Cohen Circle (the “Business Combination”), which will make Kyivstar Group Ltd. a U.S.-listed company.

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Breakthrough T1D-Authored Paper Paves the Way for Beta Cell Replacement Therapies on the Path to Cures for Type 1 Diabetes

Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits NEW YORK, Aug....

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers